Ali Hashtroudi Guy’s & St Thomas’ NHS OHS FOM Representative to UKAP

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Egyptian Guidelines For Management of Chronic Hepatitis B
1. Interpret a positive HBeAg, Anti- HBcAg, and/or anti-HCV test.
1 National Guidelines on Blood-Borne Pathogens Dr Blánaid Hayes, FRCPI, FFOM, Occupational Health Department, Beaumont Hospital, Dublin.
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
CORRELATION BETWEEN HBSAG LEVEL AND VIRAL LOAD
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
1 Blood borne occupational health risks Terhi Heinäsmäki, MD March 10, 2004 Tartu, Estonia.
Hepatitis B 101 Clinical presentation of Hepatitis B Virus (HBV) indistinguishable from other hepatitis causes and is quite variable from asymptomatic.
Acute Viral Hepatitis. Viral Hepatitis Infectious: Hepatitis A Infectious: Hepatitis A Serum : Hepatitis B, D Serum : Hepatitis B, D NANB : Hepatitis.
HEPATITIS B MARKERS AND VACCINE
Iva Pitner Mentor: A. Žmegač Horvat
Kerriann Parchment GI CBL 2 Part 3 December 2012 Viral hepatitis serology.
Washington D.C., USA, July 2012www.aids2012.org HCV genotype and HBV co-infection associate with HCV clearance in HIV- positive subjects Yuan Dong,
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
Overview National Hepatitis B Data
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
Viral Hepatitis Australian Family Physician Vol. 30 No.5, May 2001 Presented by 郭詠怡 Date presented:25/8/2003.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
Promoting Healthy Lifestyles and a Clean and Safe Environment Maximizing health department resources to identify and prevent.
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
HIV diagnosis (general) ImmunoassaysNAT (PCR)
Department of Medicine Grand Rounds Clinical Vignette Wednesday, March 4, 2009 Peter Shue, M.D.
Module 4: Testing and monitoring. Module 5: Testing and monitoring Module goal To introduce participants to best practice regarding the different tests,
SPECIAL CONSIDERATIONS August
Hepatitis B The Basics David Wong University of Toronto March 2005.
Discussion HBV Flare AWACC Pathogenesis of HBV CLDx Hepatic damage  predominantly immune mediated - cytotoxic T cells HBV specific peptides presented.
Sub module 3 Pre-ART and ART registers. Purpose of registers Key individual information for: Facilitating patient management by the identification of.
Prevalence of hepatitis B and C viruses among human immunodeficiency virus infected children in Northern Nigeria. Pennap GRI, Yahuza, AJ and Abdulkarim,
Isolated Hepatitis B Core Antibody
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
Hepatitis B screening and vaccination for Slovak Roma population in Sheffield. Age >16 1/Start standard schedule of hepatitis B vaccination if history.
MICROBIOLOGY IRS. Gastroenteritis 1) Major cause of infantile death 2) Feacal-oral transmission 3) Gastroenteritis cause dehydration 4) 50 % of all causes.
Annual Report 2012 Sharp Injuries and Body Fluid Exposure:- NumberPercentage Physicians2736% Nursing Staff3546.7% Technicians56.6% HK Staff810.7% TOTAL75***
Hepatitis B virus infection in renal transplant recipients
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Treatment of HBV/HCV Coinfection
PrEP Case Consultation
Hepatitis C in MSMs; a review of testing practices in the GUIDe clinic & a description of recent cases N. Lynn*, J Dean**, e quinn**, G Farrell*, C Murray*
PI project: Hepatitis B prophylaxis in patients with malignancies
Hepatitis Tutoring By Alaina Darby.
In The Name of God.
MICROBIOLOGY PRACTICAL
Dr Renos Ioannou GPST2 NHS Lothian
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Knowledge of transmission Sharing of sharp objects
POST EXPOSURE PROPHYLAXIS IN HCW
MICROBIOLOGY PRACTICAL
Hepatitis B and C management pathways in prison:
Volume 67, Issue 2, Pages (August 2017)
FACILITATOR VERSION Case Four: I just have antibodies to this
VL patient support: General education at different levels
Risk of Treatment Failure: Patient Support approaches and strategies
R. Cavallo  Clinical Microbiology and Infection 
Treating Hep C with Novel Agents
Expanding the Universe of Viral Hepatitis Treaters
Hepatitis Primary Care: Clinics in Office Practice
Case Four: I just have antibodies to this
HBV Infection: Some Sobering Facts
HBV Care Models: Community Collaborations for Best Practices
Evaluation of the Patient With HCV Infection
Suna Yapali, Nizar Talaat, Anna S. Lok 
HIV Testing Algorithm HIV Ag Ab with Reflex (>2 y/o and older)*
Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B  W.-K. Seto, D. K.-H. Wong,
FACILITATOR VERSION Case Four: I just have antibodies to this
Scott K. Fung, Anna S.F. Lok  Clinical Gastroenterology and Hepatology 
Presentation transcript:

Ali Hashtroudi Guy’s & St Thomas’ NHS OHS FOM Representative to UKAP EPP Clearance HEOPS 12/01/2018 Ali Hashtroudi Guy’s & St Thomas’ NHS OHS FOM Representative to UKAP

Patient safety ~ Restriction Background Exposure prone procedure Bleed back = inside AND not see AND sharp Purpose Patient safety ~ Restriction

New Guidance HBV Natural history Different markers Acute vs. chronic HBsAg HBsAb HBeAg HBeAb HBcAb HBV DNA

Review HBV HBsAg + =infected HBsAb >10 =immune HBeAg + = highly infective HBeAb useless HBcAb + = past exposure HBV DNA VL = the higher VL the more infective geq/ mL ~ IU/mL, conversion 3 to 5

Existing Guidance HBV New HBsAg -, cleared HBsAg + ↓ HBeAg +, can’t do EPP HBeAg – HBV DNA VL <103 geq 103 and 105 >105

Existing Guidance HBV New HBV DNA VL ↓ <103 geq 103 and 105 >105 ↓ ↓ ↓ Cleared Annual HBV DNA VL, 2 samples by the ref labs Antiviral treatment VL <103 Cleared Quarterly HBV DNA VL 1 sample by the ref labs Can’t do EPP

Existing Guidance HBV New HBsAg -, cleared HBsAg + ↓ HBeAg +, can’t do EPP HBeAg – HBV DNA VL <103 geq 103 and 105 >105 HBsAg -, cleared HBsAg + ↓ HBeAg, role? HBV DNA VL <103 geq (200 IU) >103

Existing Guidance HBV New HBV DNA VL ↓ <103 geq 103 and 105 >105 ↓ ↓ ↓ HBV DNA VL ↓ <103 geq >103 ↓ ↓ Cleared Annual HBV DNA VL, 2 samples by the ref labs Can’t do EPP Antiviral treatment When VL <103 cleared for EPP Quarterly HBV DNA VL 1 sample by the ref labs Can’t do EPP Cleared Annual HBV DNA VL, 2 samples by local lab Can’t do EPP Antiviral treatment Can do EPP when VL <103 Quarterly HBV DNA VL 1 sample by local lab

New Guidance HBV Treatment is only to allow EPP Not clinically indicated Guidance on how to deal with increasing HBV DNA Reference lab if >60 Designated hepatologist ?? 4 weeks between two initial samples to clear Specialist OHP UKAP Register New system of reminders

HIV HIV Ag/Ab-, cleared HIV Ag/Ab + ↓ HIV RNA VL <200 >200 ↓ ↓ <200 >200 ↓ ↓ Can do EPP Elite controller Quarterly monitoring local lab Can’t do EPP ART Can do EPP when VL <200 Quarterly monitoring local lab

Guidance HIV Action points at 50 (consider repeat) and 200 (repeat) and 1000 (stop, repeat, risk assess) Liaison with HIV specialist IVS?? Three month (12 to 16 weeks) between two initial samples to clear Quarterly (10 to 14 weeks) monitoring Specialist OHP UKAP Register New system of reminders

HCV HCV Ab-, cleared HCV Ab + ↓ HCV RNA PCR Negative Positive ↓ ↓ ↓ ↓ Cleared (Hx) No monitoring Can’t do EPP Antiviral treatment Can do EPP when PCR negative for 6/12 post treatment, one additional review 6/12 later (one year post treatment), no further monitoring

Others Consolidated guidance is Green Book style Look back exercise Transfer Plan how to deal with BFE Recall system, new UKAPOHR reminder Conditions = consent to communicate/ attendance / reporting accidents / reporting change in health / adherent to treatment

Thanks you Aliasad.hashtroudi@gstt.nhs.uk